Darinaparsin: First Approval

Darinaparsin (Darvias ® ), an organoarsenic drug, is a novel mitochondrial-targeted anticancer agent currently being developed by Solasia Pharma K.K for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). An intravenous formulation of darinaparsin has been approved for the tre...

Full description

Saved in:
Bibliographic Details
Published in:Drugs (New York, N.Y.) N.Y.), 2022-11, Vol.82 (16), p.1603-1609
Main Author: Frampton, James E.
Format: Article
Language:English
Subjects:
AdisInsight Report
Agreements
Anticancer properties
Antitumor agents
Apoptosis
Arsenic
Cancer
Cell cycle
Collaboration
Developmental stages
Electrolytes
Internal Medicine
Intravenous administration
Lymphocytes T
Lymphoma
Medicine
Medicine & Public Health
Mitochondria
Oncology
Pharmaceuticals
Pharmacokinetics
Pharmacology/Toxicology
Pharmacotherapy
Plasma
Signal transduction
T-cell lymphoma
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Darinaparsin (Darvias ® ), an organoarsenic drug, is a novel mitochondrial-targeted anticancer agent currently being developed by Solasia Pharma K.K for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). An intravenous formulation of darinaparsin has been approved for the treatment of relapsed or refractory PTCL in Japan, and preparation for the next stage of the clinical development program for this indication is currently underway in China, the USA and the EU. This article summarizes the milestones in the development of darinaparsin leading to this first approval for relapsed or refractory PTCL.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-022-01795-z